Filing Flows › Sutro Biopharma (STRO) › Q1 2026 › vs Q4 2025
Sutro Biopharma (STRO) Q1 2026 vs Q4 2025 (quarter over quarter)
Sutro Biopharma's revenue rose $2.9M (+25%) from $11.6M in Q4 2025 to $14.5M in Q1 2026.
Sutro Biopharma, Q1 2026: revenue $14.5M (-16% year over year), operating margin -204.2%, net loss $38.5M, operating cash flow −$42.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $14.5M | $11.6M | $2.9M | +25% |
| Income tax benefit | $15K | $82K | −$67K | -82% |
| Net loss | $38.5M | $46.8M | −$8.3M | -18% |
| Costs & expenses | $53.0M | $58.5M | −$5.5M | -9% |
| Operating costs | $44.2M | $49.7M | −$5.5M | -11% |
| Interest & other, net | $8.8M | $8.8M | $48K | +0.5% |
| Research & development | $36.6M | $36.6M | −$89K | -0.2% |
| General & admin | $7.6M | $8.7M | −$1.1M | -12% |
| Operating cash sources | $45.1M | $29.7M | $15.4M | +52% |
| Depreciation & amortization | $1.3M | $1.6M | −$346K | -21% |
| Share-based compensation | $1.6M | $1.7M | −$93K | -6% |
| Cash used in operations | $42.3M | $26.4M | $15.8M | +60% |
| Net loss absorbed | $38.5M | $46.8M | −$8.3M | -18% |
| Working capital & other | $6.6M | −$17.0M | $23.7M | — |
Questions
How much did Sutro Biopharma's revenue grow quarter over quarter in Q1 2026?
Sutro Biopharma's revenue rose $2.9M (+25%) from $11.6M in Q4 2025 to $14.5M in Q1 2026.